Hướng dẫn chẩn đoán và điều trị bệnh xơ cứng rải rác
Từ khóa:
Xơ cứng rải rácTải xuống
Đã Xuất bản
Cách trích dẫn
Tóm tắt
Xơ cứng rải rác (multiple sclerosis-MS) là bệnh tự miễn của hệ thần kinh trung ương, đặc trưng bởi viêm mất myelin mạn tính, tăng sinh thần kinh đệm (tạo mảng hoặc sẹo) và mất neuron thần kinh, diễn biến có thể tái phát từng đợt hoặc tiến triển. Những mảng mất myelin thường phát triển ở những thời điểm khác nhau và ở những vị trí khác nhau của hệ thần kinh trung ương (rải rác theo không gian và thời gian).
Các triệu chứng và dấu hiệu thần kinh là biểu hiện của những ổ tổn thương và sự lan rộng của những ổ mất myelin, xảy ra chủ yếu ở chất trắng của não, tủy, hoặc dây thần kinh thị giác.
Tài liệu tham khảo
Cree BAC, Hauser SL. Multiple Sclerosis,. Harrison's Principles of Internal Medicine, . 20 ed. McGraw-Hill Education: New York, NY.; 2018.
MS International Federation. Atlas of MS 3rd edition. Part 1: Mapping multiple sclerosis around the world epidemiology findings. https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. 2020.
https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. 2020.">
Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14(2): 183-93.
Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021; 14: 17562864211039648.
Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol 2014; 72 Suppl 1: 1-5.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
The National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. NICE guideline. https://www.nice.org.uk/terms-andconditions#notice-of-rights) 2022
https://www.nice.org.uk/terms-andconditions#notice-of-rights) 2022">
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-73.
Baskaran AB, Grebenciucova E, Shoemaker T, Graham EL. Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist. J Clin Neurol 2023; 19(3): 217-29.
Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol 2014; 122: 513-62.
Lim EC, Seet RC. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol 2010; 6(11): 624-36.
World health Organization. Proposal for inclusion of multiple sclerosis disease-modifying therapies (DMTs) on the complementary WHO Model Lists of Essential Medicines. World health Organization. 2022.
Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord 2020; 37: 101459.
Wise J. Multiple sclerosis: NICE recommends treatment for secondary progressive MS. BMJ 2020; 371: m3990.
Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med 2020; 133(12): 1380-90 e2.
Zéphir H, Durand-Dubief F, Le -Page E. Fiches pratiques thérapeutiques pour la prise en charge des patients atteints de sclérose en plaques. Practical treatment sheets for multiple sclerosis. Pratique Neurologique 2023; 14(2):: 98-107.
Limmroth V. Treatment of relapsing-remitting multiple sclerosis: current and future algorithms. Eur Neurol 2014; 72 Suppl 1: 35-8.
Carod-Artal FJ, Adjamian P, Vila Silvan C, Bagul M, Gasperini C. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Rev Neurother 2022; 22(6): 499-511.
Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2018; 24(12): 1594-604.
Lee M, O'Brien P. Pregnancy and multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79(12): 1308-11.
Reeve K, On BI, Havla J, et al. Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Syst Rev 2023; 9(9): CD013606.
Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90(17): 777-88.
The National Institute for Health and Care Excellence. Cladribine for treating relapsing–remitting multiple sclerosis. NICE guideline. https://www.nice.org.uk/guidance/ta616). 2019.
https://www.nice.org.uk/guidance/ta616). 2019.">
Dargahi N, Katsara M, Tselios T, et al. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci 2017; 7(7).
Ministry of Health Malaysia. Management of multiple sclerosis. Clinical practice guidelines MOH/P/PAK/293.15(GU). 2015.
Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 2018; 25(2): 215-37.
Thompson AJ. Commentary on the ECTRIMS-EAN guideline for pharmacological treatment of multiple sclerosis. Ther Adv Neurol Disord 2018; 11: 1756286418770378.
Nonino F, Baldin E, Ridley B, Casetta I, Iuliano G, G. F. Azathioprine for people with multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No.: CD015005. DOI: 10.1002/14651858.CD015005.
Ramo-Tello C, Blanco Y, Brieva L, et al. Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses. J Pers Med 2021; 12(1).
Coyle PK. Multiple sclerosis in pregnancy. Continuum (Minneap Minn) 2014; 20(1 Neurology of Pregnancy): 42-59.
Multiple Sclerosis International Federation. MSIF's Off-Label Treatments recommendations for low-resource settings. https://www.msif.org/molt-guidelines-azathioprine-rituximab/. 2023.
https://www.msif.org/molt-guidelines-azathioprine-rituximab/. 2023.">
Multiple Sclerosis International Federation. MSIF Essential Medicines Panel (MEMP) Guidelines for essential disease-modifying therapies for multiple sclerosis for low-resource settings. https://www.msif.org/wp-content/uploads/2023/01/MEMP_EtD-and-recommendations_public_201222.pdf. 2023.
https://www.msif.org/wp-content/uploads/2023/01/MEMP_EtD-and-recommendations_public_201222.pdf. 2023.">
Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95(2): 284-92.
Miller AE, Chitnis T, Cohen BA, et al. Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. JAMA Neurol 2021; 78(2): 241-6.
